Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jul 11, 2023 1:56pm
165 Views
Post# 35535852

RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsFurther ot Fiercebiotech - Pfizer and Seagen announced their proposed merger on March 12. Then on May 12, each filed notifications with the FTC and the Department of Justice. Four days later, the FTC filed its suit in federal court to halt the proposed merger between Amgen and Horizon. The move was the first by the FTC in more than a decade against a pharma M&A deal.

A month later, on June 14, 2023, Pfizer withdrew its notification for its proposed $43 billion acquisition of cancer drug specialist Seagen, stating that it would submit another notification later on the same day. No such notification has been filed thus far.


https://www.fiercepharma.com/pharma/ftc-eyeing-deal-pfizer-refiles-notification-43b-buyout-seagen

https://d18rn0p25nwr6d.cloudfront.net/CIK-0001060736/4e87c484-76b7-43f1-97a4-f789baa3cc58.pdf
<< Previous
Bullboard Posts
Next >>